SCHEMBL1096649

SCHEMBL1096649

CN(Cc1ccc(F)cc1)C(=O)c1cncn1C1c2ccccc2C(=O)OC1(C)C

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 1/20 0.60
IDO1 P14902 3/20 0.44
PRMT5 O14744 1/20 0.39
WDR77 Q9BQA1 1/20 0.39
MAPT P10636 2/20 0.37
LMNA P02545 2/20 0.37
ALDH1A1 P00352 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
USP1 O94782 2/20 0.37
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2B6 P20813 1/20 0.34
NSD2 O96028 1/20 0.34
KMT2A Q03164 1/20 0.34
GPBAR1 Q8TDU6 1/20 0.34
ATM Q13315 1/20 0.33
POLB P06746 1/20 0.33
TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1097449 0.88 CYP11B2 (0.60) CYP11B2IDO1MAPTLMNAALDH1A1
SCHEMBL1096713 0.83 CYP11B2 (0.61) CYP11B2IDO1MAPTALDH1A1NPC1
SCHEMBL1099042 0.78 CYP11B2 (0.73) CYP11B2IDO1CYP3A4
SCHEMBL1097382 0.78 CYP11B2 (0.73) CYP11B2IDO1ALDH1A1TDP1
SCHEMBL1098831 0.76 CYP11B2 (0.79) CYP11B2IDO1ALDH1A1
SCHEMBL1098830 0.76 CYP11B2 (0.79) CYP11B2IDO1ALDH1A1
SCHEMBL1097775 0.76 CYP11B2 (0.66) CYP11B2IDO1ALDH1A1
SCHEMBL1096266 0.75 CYP11B2 (0.69) CYP11B2IDO1CYP3A4
SCHEMBL1096267 0.75 CYP11B2 (0.69) CYP11B2IDO1CYP3A4
SCHEMBL1096719 0.75 CYP11B2 (1.00) CYP11B2IDO1MAPTLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153674-B2 Organic compounds NOVARTIS AG (CH) 2012-04-10 US disclosed
US-8153674-B2 Organic compounds NOVARTIS AG (CH) 2012-04-10 US disclosed
US-20090182007-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-07-16 US disclosed
WO-2007117982-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090182007-A1 ORGANIC COMPOUNDS REN, CYP17A1, HSD17B1 CYP11B2 28/4885IDO1 2430/4885PRMT5 3004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.